This shows that the 1,4-naphthoquinone, SNQA (5), is a potential PPAR-γ agonist similar to the well-known thiazolidinediones and supports our findings and potential for the treatment of IBD. The gene discussed is PPARG; the disease is inflammatory bowel disease.